Logo
LOGIN
SIGN UP
Logo

Archive

Dive into a collection of past posts and rediscover timeless content.
Tesla’s Rally Setup Is Here—But Valuation Makes It Fragile

Feb 14, 2026

•

3 min read

Tesla’s Rally Setup Is Here—But Valuation Makes It Fragile

A bounce off $390 and fresh momentum — plus $500+ analyst targets — give bulls a clear rally path. But a broken uptrend and stretched valuation leave the rebound fragile; a failed bounce could trigger a deeper sell-off.

IREN Bounces Back: The Market Votes Yes as Big Banks Step In

Feb 13, 2026

•

3 min read

IREN Bounces Back: The Market Votes Yes as Big Banks Step In

Goldman- and JPMorgan-led $3.6B financing and a 1.6 GW Oklahoma campus fund GPU expansion without diluting shareholders. Backed by a $9.7B Microsoft deal, investors are reclassifying IREN as an AI infrastructure growth story — not just a crypto miner.

AI Power Crunch: Why Bloom Energy Is the Hidden Winner

Feb 12, 2026

•

1 min read

AI Power Crunch: Why Bloom Energy Is the Hidden Winner

How Bloom’s on-site DC fuel cells and lightning-fast deployments bypass grid delays, turning a clean‐energy maker into a profitable, institutional‐backed infrastructure play for the AI boom.

Energy Is Leading in 2026—But Are the Oil Majors Cracking?

Feb 11, 2026

•

3 min read

Energy Is Leading in 2026—But Are the Oil Majors Cracking?

Energy's 18% YTD rally has outpaced the market — but mixed Q4 results and cautious guidance from Exxon, Chevron, Conoco and Shell raise questions about Big Oil’s staying power. Still, rising demand forecasts and cost-cutting plans keep the longer-term case alive, with ETFs like XLE offering a lower-risk way to play the theme.

3 Consumer Staples Stocks Breaking Out This Month

Feb 10, 2026

•

3 min read

3 Consumer Staples Stocks Breaking Out This Month

As investors rotate out of volatile tech, three defensive, dividend‐paying consumer staples — Procter & Gamble, Reynolds and Constellation Brands — are flashing technical breakouts and fresh upside potential.

BioTech Breakout: MoonLake Up 30% On FDA Wins

Feb 9, 2026

•

3 min read

BioTech Breakout: MoonLake Up 30% On FDA Wins

FDA Fast Track for Sonelokimab and an OK on HS filings have de‐risked MoonLake’s nanobody program and triggered the 30% rally. With cash into 2027 and key data readouts ahead, momentum could intensify as shorts face pressure.

Microchip Technology Says the Slump Is Ending—The Stock Is Starting to Agree

Feb 8, 2026

•

3 min read

Microchip Technology Says the Slump Is Ending—The Stock Is Starting to Agree

Q3 marks a clear turnaround as revenue, margins and cash flow recover. Analyst upgrades and renewed institutional buying point to meaningful upside if MCHP clears the key ~$80 resistance.

Which Mining Firms Are Striking It Rich in the Metals Rally?

Feb 7, 2026

•

3 min read

Which Mining Firms Are Striking It Rich in the Metals Rally?

Gold's rally has powered triple-digit gains across miners. We examine Hecla, Coeur and Kinross — winners driven by strong production, strategic M&A and robust cash returns.

Meta Platforms Posted Its Fastest Growth Guide in Years—Now What?

Feb 6, 2026

•

2 min read

Meta Platforms Posted Its Fastest Growth Guide in Years—Now What?

Meta’s 30% Q1 2026 sales guidance reignited the rally and pushed analysts to raise targets — consensus implies roughly 20–25% upside, with some forecasts as high as ~62%. The question now is whether Meta can convert heavy spending into sustained growth or if execution risk will curb the optimism.

Teradyne Inc: Sky’s the Limit for This Market, Until It Isn't

Feb 5, 2026

•

3 min read

Teradyne Inc: Sky’s the Limit for This Market, Until It Isn't

AI-fueled GPU and HBM demand — plus blowout 2026 guidance and widening margins — have pushed Teradyne to record highs. But concentrated institutional ownership and lofty expectations leave the stock vulnerable to a sharp correction.

Load more

The Markets Daily

News and insights for the market’s hottest stocks.

  • Home
  • About
  • Archive
  • Privacy Policy
  • Contact Us